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Infections with Shiga toxin-producing Shigella dysenteriae type 1 or Shiga-like toxin (SLT)-producing Esch-
erichia coli cause bloody diarrhea and are associated with an increased risk of acute renal failure and severe
neurological complications. Histopathological examination of human and animal tissues suggests that the
target cells for toxin action are vascular endothelial cells. Proinflammatory cytokines regulate endothelial cell
membrane expression of the glycolipid globotriaosylceramide (Gb3) which serves as the toxin receptor, sug-
gesting that the host response to the toxins or other bacterial products may contribute to pathogenesis by
regulating target cell sensitivity to the toxins. We examined the effects of purified SLTs on human peripheral
blood monocytes (PBMn) and two monocytic cell lines. Undifferentiated THP-1 cells were sensitive to SLTs.
Treatment of the cells with a number of differentiation factors resulted in increased toxin resistance which was
associated with decreased toxin receptor expression. U-937 cells, irrespective of maturation state, and PBMn
were resistant to the toxins. U-937 cells expressed low levels of Gb3, and toxin receptor expression was not
altered during differentiation. Treatment of monocytic cells with tumor necrosis factor alpha (TNF-a) did not
markedly increase sensitivity or alter toxin receptor expression. Undifferentiated monocytic cells failed to
synthesize TNF and interleukin 1b when treated with sublethal concentrations of SLT type I (SLT-I), whereas
cells treated with 12-O-tetradecanoylphorbol-13-acetate acquired the ability to produce cytokines when stim-
ulated with SLT-I. When stimulated with SLT-I, U-937 cells produced lower levels of TNF than PBMn and
THP-1 cells did.
The Shiga toxin family is composed of bacterial proteins that
(i) share an AB5 holotoxin molecular structure, (ii) act as 28S
rRNA N-glycosidases to inhibit eukaryotic protein synthesis,
and (iii) utilize the neutral glycolipid globotriaosylceramide
(Gb3) as the primary functional toxin receptor (for reviews, see
references 1, 20, and 22). The prototype toxin of the family,
Shiga toxin, is produced by Shigella dysenteriae type 1. A lim-
ited number of serotypes of Escherichia coli, collectively re-
ferred to as enterohemorrhagic E. coli, synthesize one or more
toxins designated Shiga-like toxins (SLTs) or verocytotoxins.
SLTs are categorized on the basis of antigenic similarity to
Shiga toxin, with the cytotoxic activity of SLT classified as type
I (SLT-I) being neutralized by polyclonal antibodies to Shiga
toxin, while Shiga-like toxin type II (SLT-II) activity is not
neutralized by the antisera (30). Subsequently, SLT-I was
shown to be essentially identical to Shiga toxin, while a number
of SLT-II toxin variants possess only ;56% homology com-
pared with Shiga toxin at the deduced amino acid sequence
level (14).
Despite efforts to improve sanitary hygiene, bacillary dysen-
tery and postdiarrheal acute renal failure (hemolytic-uremic
syndrome) continue to cause excessive morbidity and mortality
in many developing nations. In 1993, the potential of entero-
hemorrhagic E. coli to cause widespread outbreaks of bloody
diarrhea with progression to life-threatening sequelae was dra-
matically highlighted in the western United States, when over
700 people became ill following the ingestion of undercooked
contaminated hamburgers. Approximately 27% of those with
bloody diarrhea were hospitalized, 8% developed systemic
complications and four children died (8). A common his-
topathological finding in patients with postdiarrheal sequelae
is the destruction of endothelial cells lining small blood vessels
in the colon, kidneys, and central nervous system (26). In vivo
studies using a number of animal models demonstrated that
purified Shiga toxin and SLTs cause vascular damage in many
of the same target organs (for a review, see reference 9). In
vitro studies utilizing human vascular endothelial cells (HVEC)
from a number of sites demonstrated a direct cytopathic effect
mediated by the toxins, although in some cases, the toxin con-
centrations necessary to manifest cytotoxicity were orders of
magnitude greater than that estimated to be circulating in the
bloodstream of infected patients (23, 33). However, when
HVEC were cultured in the presence of the toxins and the
proinflammatory cytokines tumor necrosis factor alpha
(TNF-a) and interleukin 1b (IL-1b), cytotoxic doses were
markedly reduced, suggesting that the cytokines sensitized the
target cells to the toxic action of SLTs (19, 33). Subsequently,
van der Kar et al. (37) showed that TNF-a and IL-1b upregu-
late the expression of Gb3 on HVEC. Obrig et al. (24) also
showed that basal levels of Gb3 expression on HVEC cultured
from different sources are variable and that small vessels in
target organs may express higher levels of Gb3. Collectively,
these data suggest that modulation of toxin receptor expres-
sion may be a critical determinant in disease progression. In
order to manifest the profound vascular damage characteristic
of the hemolytic-uremic syndrome, two signals may be needed:
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circulating SLTs and elevated levels of toxin receptor-modu-
lating cytokines.
Cells of the monocyte/macrophage lineage have been shown
to be crucial in orchestrating the immune response to microbes
and microbial products (for a review, see reference 36). This
cellular control is mediated by both the induction of mem-
brane-associated signaling molecules and the synthesis and
secretion of soluble cytokines. Murine macrophages produced
TNF-a and IL-1 when stimulated in vitro with purified (endo-
toxin-free) SLTs, suggesting that macrophages may indeed
play a central role in providing the cytokines necessary for
target cell sensitization (3, 32). However, these studies have
been limited to the use of thioglycolate-elicited peritoneal
macrophages, i.e., cells isolated in an activated state. Barrett et
al. (4) reported that the administration of bacterial endotoxin
after purified SLT-II enhanced lethality, while the pretreat-
ment of rabbits with endotoxin 20 h before SLT challenge
afforded significant protection. These experiments suggest that
the state of macrophage differentiation or activation is impor-
tant in determining the cellular response to SLTs. In experi-
ments reported here, we extended our examination of the
cytotoxicity and cytokine induction capacity of SLTs by using
human peripheral blood monocytes (PBMn) and two mono-
cytic cell lines. The use of monocytic cell lines affords us the
opportunity to measure differences in cell response to the
toxins as a function of cellular differentiation.
MATERIALS AND METHODS
Toxins. SLT-I was purified as previously described (32). Purified SLT-IIe (pig
edema toxin) was the gift of James E. Samuel, Texas A&M University Health
Science Center. Prior to use, toxin preparations were passed through ActiClean
Etox columns (Sterogene Bioseparations, Arcadia, Calif.) to remove residual
endotoxin contaminants. Toxin preparations contained ,0.1 ng of endotoxin per
ml as determined by Limulus amoebocyte lysate assay. Radioiodinated SLT-I
was prepared with Na125I and Iodogen beads (Pierce Chemical Co., Rockford,
Ill.). Purified lipopolysaccharides (LPS) derived from E. coli O111:B4 were
purchased from Sigma Chemical Co., St. Louis, Mo.
Cells. Human PBMn were derived from blood collected by venipuncture from
healthy adult volunteers. Mononuclear cells were separated by Histopaque 1077
(Sigma) gradient centrifugation, and plastic-nonadherent cells were removed
after 1 h of incubation at 378C. Human myelogenous leukemia cell lines THP-1
(35) and U-937 (31) were purchased from American Type Culture Collection,
Rockville, Md., and maintained in RPMI 1640 (GibcoBRL, Grand Island, N.Y.)
supplemented with penicillin (100 U/ml), streptomycin (100 mg/ml), amphoter-
icin B (2 mg/ml), and 10% fetal bovine serum (FBS; Intergen, Purchase, N.Y.) at
378C in 5% CO2 in a humidified incubator. Vero cells were cultured in medium
199 (Celox, Hopkins, Mich.) with the supplements listed above.
Macrophage differentiation. To induce the human monocytic cell lines to a
mature macrophage-like state, THP-1 and U-937 cells (106 cells per ml) were
treated for 48 h with 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma) at 50
ng/ml for THP-1 cells or 100 ng/ml for U-937 cells. Differentiated adherent cells
were washed twice with cold Dulbecco’s phosphate-buffered saline (PBS; Gib-
coBRL) and incubated with fresh medium lacking TPA for 48 h prior to use in
assays. TPA treatment resulted in an approximately 50% reduction in intracel-
lular protein kinase C levels, as assessed by a colorimetric protein kinase C assay
kit (Pierce). In some experiments, cells were stimulated for 3 to 5 days (with daily
changes of the medium) with supplemented RPMI 1640 containing 50 ng of
1a,25-dihydroxyvitamin D3 (Sigma) per ml, 40 ng of recombinant human gran-
ulocyte-macrophage colony-stimulating factor (R&D Systems, Minneapolis,
Minn.) per ml, 500 U of recombinant human gamma interferon (GibcoBRL) per
ml, or 0.25 mM n-butyric acid (Sigma). The cells were washed with PBS prior to
use. Several techniques were used to assess monocyte differentiation. (i) Percent
adherence of cells to plastic was determined by hemacytometer counts of cells
before and after stimulation with differentiation factors. (ii) Phagocytic index was
determined by internalization of fluorescein-conjugated latex beads. (iii)
Changes in membrane CD14 expression were measured by flow cytometry with
a fluorescein-conjugated murine monoclonal immunoglobulin G2a (IgG2a) di-
rected against human CD14 (UCHM-1; Research Diagnostics, Flanders, N.J.).
Cytotoxicity assays. Vero cells were plated at ;104 cells per well, and human
monocytic cells were plated at ;105 cells per well in 96-well microtiter plates.
Purified toxin preparations were serially diluted (1.0 mg/ml to 0.1 pg/ml) in
medium 199 or RPMI 1640 and 100-ml portions of each dilution were transferred
to the cells in six replicate wells. All cells were incubated with the toxins for 48
h at 378C in 5% CO2. Twenty-five microliters of a 5-mg/ml stock solution of
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma) was
added to the cells, and incubation was continued for 2 h. The cells were lysed,
and the insoluble formazan dye was extracted for 4 h at 378C with 50% N,N-
dimethylformamide and 20% sodium dodecyl sulfate. A570 was measured (Dyn-
atech MR5000; Dynatech Laboratories, Chantilly, Va.), and percent viability was
calculated as follows: [(A570 of toxin-treated cells 2 A570 background)/(A570 of
untreated cells 2 A570 background)] 3 100. The 50% cytotoxic dose (CD50) is
the amount of toxin necessary to kill 50% of the cells in a well.
Cytokine assays. TNF bioactivity in supernatants collected from untreated
cells and cells treated with SLT-I or LPS for 18 h was determined by the lysis of
actinomycin D (Act D)-treated L929 murine fibroblasts (32). Briefly, L929 cells
were cultured in 96-well microtiter plates at a density of 2 3 105 cells per ml in
Iscove’s modified Dulbecco’s medium (Mediatech, Washington, D.C.) supple-
mented with 5% FBS at 378C in 5% CO2 in a humidified incubator. Dilutions of
FIG. 1. Comparison of cytotoxicities of purified SLTs for human PBMn and monocytic cell lines. Cells were incubated with 10-fold dilutions of purified SLT-I (A)
or SLT-IIe (B) in six replicate wells for 48 h at 378C. Viability was determined with the dye MTT. Control cells incubated in medium alone were used to calculate percent
viability. The data shown in panels A and B are derived from eight and two independent experiments, respectively. Symbols: , undifferentiated U-937 cells; ,
differentiated U-937 cells; h, undifferentiated THP-1 cells; n, differentiated THP-1 cells; E, human PBMn; F, Vero cells.
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macrophage supernatants or recombinant human TNF-a (R&D Systems) were
made in medium containing 1 mg of Act D per ml (Sigma). Each dilution was
added to five replicate wells of L929 cells and incubated for 18 h. MTT was added
to each well, and after a 2-h incubation, the cells were lysed and the formazan dye
was extracted from the cells. A570 was measured, and L929 survival values were
calculated as follows: (A570 of L929 cells treated with supernatants plus ActD)/
(A570 of L929 cells treated with ActD only). TNF bioactivity in each sample was
calculated by substituting the corresponding survival value in the regression
equation generated by the recombinant human TNF-a standard curve. Treat-
ment of L929 cells with Act D and SLT-I consistently resulted in ,10% cyto-
toxicity compared with untreated cells. Levels of immunoreactive IL-1b in su-
pernatants collected from cells exposed to stimulants for 24 h were measured by
an enzyme-linked immunosorbent assay (ELISA) (R&D Systems). Statistical
analyses using Student’s paired t test were performed with Microsoft Excel
version 4.0 software (Microsoft Corp., Redmond, Wash.).
Toxin receptor expression. Relative levels of cell surface toxin receptor ex-
pression were evaluated by indirect immunofluorescence (33). Briefly, 106 cells
per ml were mixed with a receptor-saturating concentration of SLT-I (;1 mg/ml)
at 48C for 1 h with constant agitation. Unbound toxin was removed by three
washes with ice-cold phenol red-free Earle’s balanced salt solution (EBSS; Gib-
coBRL) containing 10% FBS and 0.1% NaN3. The cells were then suspended in
500 ml of a 1:100 dilution of MAb 13C4, a murine monoclonal IgG1 directed
against SLT-I B subunits (29), and agitated for 45 min at 48C. Unbound primary
antibody was removed by washes with cold EBSS, and the cells were treated with
a 1:100 dilution of fluorescein isothiocyanate-conjugated goat F(ab9)2 anti-
mouse IgG (Organon-Teknika, Durham, N.C.) for 45 min at 48C. Cells were
washed with EBSS lacking FBS and placed in a flow cytometer (EPICS V;
Coulter Electronics, Hialeah, Fla.) equipped with an argon laser tuned to 488
nm. Fluorescence intensity of 104 events was recorded. Integration analyses were
performed with the Coulter Easy 88 system. Controls included cells in which
primary or secondary antibodies had been excluded and cells treated with an
isotype-matched primary monoclonal antibody directed against an irrelevant
antigen.
Toxin internalization studies. Toxin internalization was measured by the tem-
perature-dependent loss of cell surface fluorescence as described by Cohen et al.
(5). Briefly, purified SLT-I (7 mg/ml) was added to 106 cells per ml at 48C for 1
h. The cells were extensively washed with EBSS. Some cells were incubated at
378C in 5% CO2 for 1 or 3 h. Control cells were maintained at 48C. All the cells
were then treated with MAb 13C4 and fluoresceinated goat anti-mouse IgG as
outlined above. Fluorescence intensity was measured by flow cytometry. Percent
internalization was calculated as [(MFI at 48C 2 MFI at 378C)/MFI at 48C] 3
100, where MFI is mean fluorescence intensity expressed as channel number 6
standard error of the mean. Radioiodinated SLT-I was also used to examine
toxin binding and internalization. Briefly, 4 3 106 cpm of 125I-SLT-I (specific
activity, 1.6 3 106 cpm/mg of protein) was added to 5 3 106 cells per ml and
incubated at 48C for 1 h to allow toxin binding and prevent internalization. All
cells were washed three times with cold RPMI 1640, and some cells were then
shifted to 378C for 1 h, while others were maintained at 48C. Cells were removed
from the culture dishes by scraping, and the radioactivity associated with cell
pellets was determined by scintillation counting. In some experiments, cells were
treated with trypsin (50 mg/ml) at room temperature for 15 min and extensively
washed prior to scintillation counting. The trypsinization procedure did not
decrease trypan blue exclusion or alter cell morphology by light microscopy.
Toxin sensitization experiments. TPA-differentiated THP-1 cells (106 cells per
ml) were cultured in RPMI 1640 supplemented with 0.25 mM n-butyric acid or
8-bromoadenosine 39:59-cyclic monophosphate (br-cAMP; Sigma) for 24 h. The
medium was removed, and fresh medium containing the sensitizing agents was
added for an additional 24 h. Cells were treated with serial dilutions of purified
SLT-I for 48 h. MTT was used to measure cytotoxicity as outlined above.
RESULTS
Comparative cytotoxicity of purified SLTs for human mono-
cytes and monocytic cell lines. The cytotoxic effects of purified
SLT-I and SLT-IIe for human PBMn and the monocytic cell
lines THP-1 and U-937 was assessed by incubation of the cells
with 10-fold dilutions of the toxins for 48 h. As shown in Fig. 1,
undifferentiated THP-1 cells were sensitive to SLT-I (CD50,
;18 pg/ml) and SLT-IIe (CD50,;10 pg/ml). TPA treatment of
THP-1 cells resulted in increased adherence of the cells to
plastic, increased phagocytic activity, and a dramatic increase
in resistance to SLTs (CD50, .1.0 mg/ml). Primary PBMn and
undifferentiated U-937 cells were refractory to the cytotoxic
effects of SLT-I and SLT-IIe, with CD50s at least 5 log units
greater than that characterized for undifferentiated THP-1
cells. Differentiation-dependent changes in toxin sensitivity
with U-937 cells were not noted. Vero cells were used as a
toxin-sensitive control cell (CD50, ;1.0 pg/ml).
Cytokine production by human monocytes and monocytic
cell lines stimulated with purified SLT-I or LPS. PBMn and
TPA-treated THP-1 and U-937 cells were incubated with
SLT-I or LPS for 18 or 24 h, and TNF bioactivity and immu-
noreactive IL-1b levels in cell-free culture supernatants were
determined by the L929 cell lysis assay or ELISA, respectively.
PBMn and THP-1 cells responded to SLT-I stimulation by
synthesizing TNF and IL-1b in a dose-dependent manner (Fig.
2). In contrast, U-937 cells were less responsive to SLT-I,
producing significantly elevated TNF activity only at the high-
est toxin dose tested (P , 0.05 by Student’s paired t test). All
the cells used in these experiments produced TNF and IL-1b
FIG. 2. Cytokine production by human PBMn and monocytic cell lines stimulated with purified SLT-I. PBMn and TPA-differentiated THP-1 and U-937 cells were
incubated with media containing the indicated concentrations of purified SLT-I for 18 h (A) or 24 h (B) at 378C. Cell-free culture supernatants were collected, and
TNF bioactivity (A) was determined by the L929 lysis assay. IL-1b levels (B) were determined by ELISA. The data shown are the means 6 standard deviations of 10
determinations from two independent experiments. The asterisk denotes nonsignificance by Student’s paired t test. All other test values differ significantly compared
with the control value (P , 0.05).
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when stimulated with LPS at doses as low as 5.0 ng/ml (data
not shown). We detected slightly elevated levels of IL-1b in
supernatants from untreated control monocytic cells, probably
caused by residual IL-1b production after TPA treatment (7).
Treatment of undifferentiated U-937 cells with SLT-I or LPS
and treatment of undifferentiated THP-1 cells with LPS did
not evoke significantly elevated TNF or IL-1b production
(data not shown). Detection of soluble cytokines produced by
SLT-treated undifferentiated THP-1 cells was complicated by
the extreme sensitivity of the cells to the toxins. However,
when undifferentiated THP-1 cells were treated with sublytic
doses of SLT-I (up to 10 pg/ml), we did not detect elevated
cytokine production (data not shown). Thus, optimal cytokine
production by human monocytic cell lines stimulated with
SLT-I or LPS required some degree of cellular differentiation.
Furthermore, as THP-1 cells acquired differentiation-associ-
ated resistance to SLTs, the cells responded to the toxins by
elaborating TNF and IL-1b.
Analysis of toxin receptor expression on human monocytic
cell lines. Several studies have demonstrated a correlation be-
tween the sensitivity of some cell lines to SLTs and membrane
expression of Gb3 (6, 11, 38). To evaluate whether the differ-
ential toxin sensitivity we observed with THP-1 and U-937 cells
was related to toxin receptor expression, we monitored Gb3
levels by indirect immunofluorescence and flow cytometry.
Mean fluorescence intensity (MFI) was used as a relative mea-
sure of Gb3 expression. In accordance with earlier studies (16),
toxin-sensitive undifferentiated THP-1 cells possessed rela-
tively high levels of toxin receptors (Fig. 3A; MFI 5 140.7 6
12.7). Consistent with their relative resistance to SLTs, undif-
ferentiated U-937 cells displayed an approximately fivefold
reduction in SLT-I binding (MFI 5 29.3 6 2.7) from that of
THP-1 cells. Vero cells, the toxin-sensitive control cell line
used in this study, exhibited Gb3 levels approximately 30%
higher (MFI 5 182.6 6 11.3) than undifferentiated THP-1
cells. These data suggest that levels of toxin receptor expres-
sion may explain, at least in part, the observed differences in
toxin sensitivity between undifferentiated THP-1 and U-937
cells.
Monocyte maturation is accompanied by the gain or loss of
a number of enzymatic activities or cell surface markers (2, 10,
17). Therefore, we evaluated whether the differentiation-asso-
ciated reduction in toxin sensitivity we observed with THP-1
cells was related to changes in toxin receptor expression. TPA
treatment of THP-1 cells resulted in an approximately 50%
reduction in cell surface fluorescence (Fig. 3B; MFI of un-
treated THP-1 cells5 140.76 12.7 versus MFI of TPA-treated
THP-1 cells 5 74.5 6 17.6). When 125I-SLT-I was used to
examine toxin binding, we detected a .2-log-unit decrease in
binding in TPA-treated THP-1 cells from that of undifferenti-
ated THP-1 cells (data not shown). TPA-treated U-937 cells
showed only a slight reduction in Gb3 expression in compari-
son to the undifferentiated counterpart (Fig. 3C; MFI of un-
treated U-937 cells 5 29.3 6 2.7 versus MFI of TPA-treated
U-937 cells 5 26.5 6 3.4). These data show that the differen-
tiation-associated resistance to SLTs we observed with THP-1
cells was associated with a decrease in membrane toxin recep-
tor expression.
FIG. 3. Toxin receptor profiles of THP-1, U-937, and Vero cells monitored
by indirect immunofluorescence and flow cytometry. Cell suspensions (106 cells
per ml) were treated with 1 mg of SLT-I per ml at 48C. Bound toxin was then
detected with a murine anti-SLT-I monoclonal antibody and a fluorescein-conju-
gated secondary antibody. The cells were extensively washed and placed in a flow
cytometer. Fluorescence emitted by 104 events was recorded. The data shown are
representative of five independent analyses. (A) Comparison of Gb3 expression
on undifferentiated cells. (B) Comparison of Gb3 expression on undifferentiated
versus differentiated THP-1 cells. (C) Comparison of Gb3 expression on undif-
ferentiated versus differentiated U-937 cells.
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Internalization of SLT-I by THP-1 and Vero cells. Our flow
cytometric analyses of THP-1 cells demonstrated a differenti-
ation-dependent reduction in SLT-I binding. However, as es-
timated from the MFIs, the amount of toxin binding to resis-
tant TPA-treated THP-1 cells was roughly 2.5 times that
binding to toxin-resistant U-937 cells. We therefore questioned
whether the toxin resistance observed for TPA-treated THP-1
cells was due to an inability to internalize membrane-bound
toxin. Temperature-sensitive toxin internalization was moni-
tored by flow cytometry (Fig. 4), and MFIs were used to cal-
culate percent internalization as described in Materials and
Methods. After 1 h of incubation at 378C, toxin-sensitive Vero
cells and undifferentiated THP-1 cells showed 77.5 and 47.2%
reduction of surface fluorescence, respectively. Although dif-
ferentiated THP-1 cells showed decreased toxin binding, the
percent loss of surface fluorescence (51.5%) was comparable
to that observed for undifferentiated THP-1 cells. To ensure
that the loss of surface fluorescence correlated with toxin in-
ternalization, we monitored the localization of 125I-SLT-I after
binding to cells at 48C and a temperature shift to 378C (Fig. 5).
When THP-1 cells were maintained at 48C, approximately 75%
of the cell-associated counts were removed by brief trypsiniza-
tion, suggesting that the toxin was not extensively internalized.
Incubation for 1 h at 378C resulted in ;56% reduction in
cell-associated radioactivity from that of cells kept at 48C, and
trypsin treatment did not result in a statistically significant loss
of radiolabel from the cells, suggesting that after the temper-
ature shift, the toxin was present in a trypsin-inaccessible (i.e.,
intracellular) form.
Modulation of toxin receptor expression on THP-1 and
U-937 cells by recombinant human TNF-a. Earlier studies
demonstrated that the treatment of HVEC with TNF-a re-
sulted in the upregulation of cell surface Gb3 expression and
increased toxin sensitivity (24, 37). To investigate whether a
similar phenomenon is operative in monocytes, we treated cells
with TNF-a (200 U/ml) for 24 h prior to SLT-I treatment and
measurement of toxin receptor expression by flow cytometry.
TNF pretreatment of undifferentiated THP-1 cells resulted in
a modest increase in toxin binding (MFI of untreated cells 5
144.9 6 37.8 versus MFI of TNF-treated cells 5 155.3 6 36.8
FIG. 4. Internalization of SLT-I by THP-1 and Vero cells. Cells (106 cells per
ml) were incubated with purified SLT-I for 1 h at 48C. After three washes with
ice-cold buffer, some cells were incubated at 378C to allow internalization and
other cells were maintained at 48C. Cell-bound toxin was detected by flow
cytometry as described in Materials and Methods. The graphs shown are repre-
sentative of five independent experiments.
FIG. 5. Binding and internalization of 125I-SLT-I by undifferentiated THP-1
cells. Radioiodinated SLT-I was incubated with 5 3 106 cells per ml at 48C for 1
h (t1). Unbound toxin was removed by washing, and the cells were either main-
tained at 48C or shifted to 378C for 1 h (t2). Cells were treated with trypsin for
15 min at room temperature or not treated with trypsin (2). Binding of 125I-
SLT-I to cells was quantitated by scintillation counting.
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[P , 0.05 by Student’s paired t test]). In contrast, TPA-treated
THP-1 cells did not respond to TNF-a pretreatment by signif-
icantly increasing membrane immunofluorescence (MFI of un-
treated cells 5 57.8 6 17.6 versus MFI of TNF-treated cells 5
60.5 6 14.6). Thus, during the course of maturation, THP-1
cells not only downregulate toxin receptor levels but also re-
main unresponsive to TNF-mediated increases in toxin recep-
tor expression. Neither undifferentiated nor TPA-treated
U-937 cells displayed statistically significant elevations in cell
surface Gb3 expression following exposure to TNF compared
with untreated cells (data not shown).
Sensitization of differentiated THP-1 cells to SLT-I toxicity.
Although TPA-treated THP-1 cells are refractory to the toxic
action of SLT-I, they bind and internalize the toxin. Using
A431 cells, a human epidermoid carcinoma cell line, Sandvig et
al. (27) noted a similar response to Shiga toxin. Furthermore,
treatment of A431 cells with the differentiation agent butyric
acid or 8-br-cAMP sensitized the cells to Shiga toxin via a
mechanism involving, in part, increased intracellular transport
of the toxin to the endoplasmic reticulum. To determine if a
similar sensitization mechanism was operating in human mono-
cytic cells, we treated differentiated THP-1 cells with n-butyric
acid or 8-br-cAMP prior to exposure to 10-fold dilutions of
SLT-I (Fig. 6). Butyrate treatment produced only a modest
increase in toxin sensitivity at the highest toxin dose tested.
However, treatment of TPA-differentiated THP-1 cells with
the cell-soluble cAMP analog sensitized the cells to the cyto-
toxic action of SLT-I (CD50, ;50 ng/ml) but did not restore
toxin sensitivity to the values characteristic of undifferentiated
THP-1 cells.
Effects of various differentiation factors on toxin receptor
expression and SLT-I cytotoxicity.We measured the effects on
toxin sensitivity and Gb3 expression of THP-1 cells using dif-
ferentiation factors which may be physiologically more rele-
vant than the pharmacologic agent TPA. Differentiation was
monitored by flow cytometric detection of the CD14 surface
antigen and estimation of percent adherence to plastic. All the
differentiation agents tested diminished the expression of
membrane toxin receptor from that of untreated cells (Table
1). Receptor reduction was as high as 46% of control cells in
TPA-treated cells, while butyrate was the least-effective mod-
ulator of toxin receptor expression. All the differentiation fac-
tors induced toxin resistance, although the extent of resistance
differed from an approximate 10-fold increase in CD50 follow-
ing butyrate treatment to a .105-fold increase in resistance
mediated by TPA or gamma interferon treatment. These data
suggest that THP-1 cell differentiation mediated by a variety of
agents is associated with decreased toxin receptor expression
and resistance to SLTs.
DISCUSSION
Although our understanding of the roles of Shiga toxin and
SLTs in the pathogenesis of bloody diarrhea and hemolytic-
uremic syndrome are at an inchoate stage, one concept that
has emerged from numerous studies is that HVEC are target
cells of toxin action. Toxin receptor expression on HVEC may
be upregulated by endogenous cytokine mediators, including
TNF-a and IL-1b (37), and exogenous modulators, such as
butyrate and vitamin D3 (18). Thus, regulation of enzymes
involved in target cell glycolipid biosynthesis and degradation
may be an important determinant in the development of the
vascular lesions characteristic of infections with SLT-produc-
ing bacteria. Macrophages may participate in pathogenesis by
producing cytokines which alter glycolipid biosynthesis and
sensitize HVEC to the toxins. The data presented here show
that plastic-adherent human PBMn are essentially resistant to
the cytotoxic action of SLTs. Two homogeneous human mono-
cytic leukemia cell lines display a differential maturation-asso-
ciated susceptibility to SLTs. Undifferentiated THP-1 cells, but
not U-937 cells, are sensitive to the cytopathic effects of SLTs.
Incubation of THP-1 and U-937 cells with phorbol diesters
results in reduced cellular replication, increased adherence to
plastic surfaces, increased phagocytic activity, and reduced
protein kinase C-dependent phosphorylation of selective en-
dogenous substrates (21, 34, 39). We show here that TPA
treatment of THP-1 cells also induces resistance to SLTs as
characterized by a CD50 of.1.0 mg/ml. In contrast, U-937 cells
are resistant to SLTs, irrespective of degree of cellular differ-
entiation. The reason for the differential response to SLTs may
be related to the developmental stage in which the cell line is
transformed. Unlike the polyploid U-937 cell line, THP-1 cells
possess a normal complement of chromosomes and are con-
sidered more representative of primary monocyte-derived
macrophages in terms of inducible functions (2, 17). Interest-
ingly, Jacewicz et al. (13) have noted the differential matura-
tion-associated response of human intestinal epithelial cell
lines to SLT-I. Thus, the differentiation stage of epithelial cells
and monocytes may be important in the development of bloody
diarrhea and systemic complications, respectively.
PBMn and TPA-treated THP-1 and U-937 cells synthesized
and secreted TNF and IL-1b when incubated with purified
SLT-I, although the dose-response studies suggested that
THP-1 cells were more responsive to TNF induction than were
FIG. 6. Toxin sensitization of differentiated THP-1 cells. TPA-treated THP-1
cells were incubated with 0.25 mM n-butyric acid or br-cAMP for 24 h at 378C.
The medium was removed, and the cells were treated with the stimulants for an
additional 24 h. Cells were then incubated with serial dilutions of SLT-I or
medium for 48 h at 378C. Cell viability was determined with the dye MTT. The
data shown were derived from five independent experiments. Symbols: h, un-
treated cells; , n-butyric acid-treated cells; F, br-cAMP-treated cells.
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U-937 cells. Thus, concomitant with a loss of susceptibility to
SLTs, monocytic cells develop the capacity to produce proin-
flammatory cytokines in response to toxin stimulation. PBMn
and TPA-treated THP-1 and U-937 cells produced elevated
levels of cytokines when treated with a well-documented cyto-
kine inducer, LPS, at doses as low as 5.0 ng/ml. Undifferenti-
ated THP-1 and U-937 cells failed to produce cytokines when
stimulated with LPS or sublytic concentrations of SLT-I.
All Shiga toxin-, SLT-I-, and SLT-II-sensitive cells express
the neutral glycolipid Gb3, and for some cell types, a correla-
tion between receptor expression and toxin sensitivity has been
demonstrated (6, 11, 38). Our studies with human monocytic
cell lines support this concept; differences in toxin receptor
expression between undifferentiated THP-1 and U-937 cells
were correlated with differences in sensitivity to the toxins.
Furthermore, treatment of THP-1 cells with differentiation
agents which reduced toxin receptor expression also rendered
the cells resistant to cell killing. As has been previously noted
(12), the correlation between toxin receptor expression and
toxin sensitivity is not linear. For example, the difference in
reduction of surface fluorescence mediated by gamma inter-
feron versus vitamin D3 treatment of THP-1 cells was approx-
imately 5%, but the difference in toxin sensitivity was approx-
imately 1,000-fold (Table 1). Thus, the proportional change in
toxin resistance was greater than the decrease in Gb3 expres-
sion. The precise reason for the nonlinear relationship be-
tween toxin receptor expression and cytotoxicity is not known,
although one would predict that if stable toxin binding and
internalization require cooperative binding between pentam-
eric B subunits and multiple Gb3 molecules, then minute re-
ductions in Gb3 expression may manifest marked differences in
cytotoxicity. An important caveat in interpreting our data is
that quantitative and qualitative differences in Gb3 may be
involved in toxin sensitivity. Modifications in the fatty acid
composition of the ceramide moiety of Gb3 may alter the
conformation or surface accessibility of the Gal(a1-4)Gal di-
saccharide necessary for toxin binding (15, 27). Subtle modifi-
cations in toxin receptor structure induced by differentiation
agents would not be detected by the methods employed in this
study.
We demonstrate here that cells of the human monocyte/
macrophage lineage respond differently to SLT-I treatment
than cells of epithelial or endothelial origin do. Unlike A431
epithelioid cells, treatment of differentiated THP-1 cells with
n-butyric acid did not restore, and treatment with br-cAMP
only partially restored, the toxin-sensitive phenotype. Unlike
HVEC, TNF-a treatment of THP-1 cells did not result in
drastic alterations in toxin receptor expression. TPA treatment
of THP-1 cells resulted in toxin resistance associated with
reduced toxin receptor expression, yet the cells still bound and
internalized SLT-I. While the precise intracellular fate of SLTs
in undifferentiated versus differentiated THP-1 cells awaits
further study, our experiments suggest that SLT binding and
internalization per se are not sufficient to cause cell death.
While treatments designed to alter the regulation of toxin
receptor synthesis and toxin processing or routing may repre-
sent effective interventional strategies to inhibit SLT cytotox-
icity, the regulation of Gb3 synthesis and intracellular transport
of SLTs may occur by distinct mechanisms in different cell
types.
In response to inflammatory stimuli, circulating PBMn ad-
here tightly to vascular endothelial cells, undergo diapedesis,
and migrate to sites of infection or tissue damage (28). In the
presence of microbial products and host response factors, a
monocyte differentiative program is activated, resulting in the
synthesis of products which direct the cells to inflamed tissue,
trigger increased major histocompatibility complex class II ex-
pression, facilitate increased phagocytosis, and activate the
cells to a microbicidal or tumoricidal state. Immunohistochem-
ical studies on rectal biopsies from patients with shigellosis
suggest that elevated levels of monocyte-activating cytokines
are found in damaged intestinal tissues (25). The abilities of
monocytes to undergo differentiation to a microbicidal state
and to extravasate to sites of bacterial invasion and tissue
damage would seem intuitively advantageous to the host. Our
data suggest that as monocytes undergo differentiation, the
cells may become increasingly refractory to the cytotoxic action
of SLTs while simultaneously acquiring the capacity to produce
TNF and IL-1b in response to the toxins. However, excessive
localized production of proinflammatory cytokines may exac-
erbate vascular damage, especially at sites expressing high
basal levels of Gb3 prior to toxin exposure. Studies to further
clarify the roles of inflammatory cells and their products in the
pathogenesis of hemorrhagic colitis and the hemolytic-uremic
syndrome are in progress in our laboratory.
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